Key Segmentation
By Service
-
Biomarker Assay Development and Validation
-
Flow Cytometry
-
Other Services
By Biomarker Type
-
Molecular Biomarkers
-
Cellular Biomarkers
By Application
-
Oncology
-
Drug Discovery and Development
-
Others
By End Use
-
Pharmaceutical and Biotechnology Companies
-
Contract Research Organizations
-
Research Institutes
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market player
Frequently Asked Questions
Key players include BioAgilytix Labs, Eurofins Scientific SE, SGS SA, Charles River Laboratories, Labcorp, Thermo Fisher Scientific Inc., ICON plc, IQVIA Holdings Inc. and Syneos Health.
Key opportunities include liquid biopsy and minimal residual disease testing, cell therapy biomarker analysis, companion diagnostic development and expanding trial activity in Asia Pacific.
The major growth factor is the spread of precision medicine, where biomarker-based patient selection and endpoints make outsourced assay services essential to drug development.
By Service, the Biomarker Assay Development and Validation segment dominated the market in 2025 with a 45.77% share, supported by regulatory demand for validated assays.
North America dominated the market with a share of 44.50% in 2025, driven by biopharmaceutical sponsors, contract research organizations and active oncology pipelines.